PMID- 36033448
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Matricellular protein tenascin C: Implications in glioma progression, 
      gliomagenesis, and treatment.
PG  - 971462
LID - 10.3389/fonc.2022.971462 [doi]
LID - 971462
AB  - Matricellular proteins are nonstructural extracellular matrix components that are 
      expressed at low levels in normal adult tissues and are upregulated during 
      development or under pathological conditions. Tenascin C (TNC), a matricellular 
      protein, is a hexameric and multimodular glycoprotein with different molecular 
      forms that is produced by alternative splicing and post-translational 
      modifications. Malignant gliomas are the most common and aggressive primary brain 
      cancer of the central nervous system. Despite continued advances in multimodal 
      therapy, the prognosis of gliomas remains poor. The main reasons for such poor 
      outcomes are the heterogeneity and adaptability caused by the tumor 
      microenvironment and glioma stem cells. It has been shown that TNC is present in 
      the glioma microenvironment and glioma stem cell niches, and that it promotes 
      malignant properties, such as neovascularization, proliferation, invasiveness, 
      and immunomodulation. TNC is abundantly expressed in neural stem cell niches and 
      plays a role in neurogenesis. Notably, there is increasing evidence showing that 
      neural stem cells in the subventricular zone may be the cells of origin of 
      gliomas. Here, we review the evidence regarding the role of TNC in glioma 
      progression, propose a potential association between TNC and gliomagenesis, and 
      summarize its clinical applications. Collectively, TNC is an appealing focus for 
      advancing our understanding of gliomas.
CI  - Copyright (c) 2022 Fu, Zhu, Luo, Chen, Dou, Chen, Zhong, Su and Liu.
FAU - Fu, Zaixiang
AU  - Fu Z
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhu, Ganggui
AU  - Zhu G
AD  - Department of Neurosurgery, Hangzhou First People's Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Luo, Chao
AU  - Luo C
AD  - Department of Neurosurgery, The Affiliated Hospital of Kunming University of 
      Science and Technology, Kunming, China.
FAU - Chen, Zihang
AU  - Chen Z
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Dou, Zhangqi
AU  - Dou Z
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Chen, Yike
AU  - Chen Y
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhong, Chen
AU  - Zhong C
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Su, Sheng
AU  - Su S
AD  - Department of Neurosurgery, The Fourth Affiliated Hospital, School of Medicine, 
      Zhejiang University, Yiwu, China.
FAU - Liu, Fuyi
AU  - Liu F
AD  - Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220812
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9413079
OTO - NOTNLM
OT  - clinical significance
OT  - glioma progression
OT  - gliomagenesis
OT  - matricellular protein
OT  - neurogenesis
OT  - tenascin C
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as potential 
      conflicts of interest.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/30 06:01
PMCR- 2022/01/01
CRDT- 2022/08/29 04:54
PHST- 2022/06/22 00:00 [received]
PHST- 2022/07/25 00:00 [accepted]
PHST- 2022/08/29 04:54 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/30 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.971462 [doi]
PST - epublish
SO  - Front Oncol. 2022 Aug 12;12:971462. doi: 10.3389/fonc.2022.971462. eCollection 
      2022.